Download full-text PDF

Source

Publication Analysis

Top Keywords

[effectiveness pyrvinium
4
pyrvinium pamoate
4
pamoate treating
4
treating strongyloidiasis]
4
[effectiveness
1
pamoate
1
treating
1
strongyloidiasis]
1

Similar Publications

Leishmaniasis, a neglected tropical disease caused by various Leishmania species, poses a significant global health challenge, especially in resource-limited regions. Visceral Leishmaniasis (VL) stands out among its severe manifestations, and current drug therapies have limitations, necessitating the exploration of new, cost-effective treatments. This study utilized a comprehensive computational workflow, integrating traditional 2D-QSAR, q-RASAR, and molecular docking to identify novel anti-leishmanial compounds, with a focus on Glycyl-tRNA Synthetase (LdGlyRS) as a promising drug target.

View Article and Find Full Text PDF

Pancreatic cancer is an intractable disease with the worst prognosis of all common cancers. The treatment regimens currently used for pancreatic cancer do not significantly impact patient survival, and therefore, effective treatment strategies are urgently needed. Drug repurposing, which identifies new indications for existing and approved drugs, has proven to be a desirable approach to anti-cancer drug discovery.

View Article and Find Full Text PDF
Article Synopsis
  • The interaction between PD-1 and PD-L1 is key for tumor immune evasion and represents a target for cancer immunotherapy, though current treatments face issues such as high costs and resistance.
  • Benzosampangine emerged from screening 511 natural compounds as a promising PD-L1 inhibitor, exhibiting strong binding affinity compared to existing controls and showcasing unique interactions with key amino acids in the active site.
  • ADMET profiling indicates that benzosampangine has advantages over control molecules in terms of solubility, permeability, and low toxicity, supporting its potential use in therapies targeting the PD-1/PD-L1 pathway.
View Article and Find Full Text PDF

Background: Cancer cells alter their metabolic phenotypes with nutritional change. Single agent approaches targeting mitochondrial metabolism in cancer have failed due to either dose limiting off target toxicities, or lack of significant efficacy in vivo. To mitigate these clinical challenges, we investigated the potential utility of repurposing FDA approved mitochondrial targeting anthelmintic agents, niclosamide, IMD-0354 and pyrvinium pamoate, to be combined with GLUT1 inhibitor BAY-876 to enhance the inhibitory capacity of the major metabolic phenotypes exhibited by tumors.

View Article and Find Full Text PDF

It has been evidenced that ROR2 influences the growth of many tumors, including non-small cell lung cancer, osteosarcoma, and breast cancer. This research examined the effect of the WNT1/ROR2 signaling pathway on the progression of triple-negative breast cancer (TNBC). Bioinformatics analysis results demonstrated that ROR2 had a higher messenger RNA (mRNA) expression level in TNBC tissues and was positively correlated with poor patient prognosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!